Unicycive Therapeutics company info

What does Unicycive Therapeutics do?
Unicycive Therapeutics (NASDAQ:UNCY) is a biotechnology firm that focuses on developing and commercializing innovative treatments for patients with kidney disease and renal conditions. Their portfolio includes Renazorb, a phosphate binder for managing hyperphosphatemia in patients with chronic kidney disease, and UNI-494, an investigational drug for the treatment of acute kidney injury, underscoring their commitment to addressing unmet medical needs in renal care. The company's objective is to improve patient outcomes and quality of life through the discovery, development, and commercialization of these novel therapeutic candidates. With a patient-centered approach, Unicycive Therapeutics strives to advance renal care and meet the complex challenges faced by individuals with kidney diseases.
Unicycive Therapeutics company media
Company Snapshot

Is Unicycive Therapeutics a public or private company?

key
Ownership
Public

How many people does Unicycive Therapeutics employ?

people
Employees
14

What sector is Unicycive Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Unicycive Therapeutics?

location pin
Head Office
California, United States

What year was Unicycive Therapeutics founded?

founded flag
Year Founded
2016
What does Unicycive Therapeutics specialise in?
/Kidney Disease /Drug Development /Therapeutic Solutions /Clinical Trials /Renal Dysfunctions /Medical Research

What are the products and/or services of Unicycive Therapeutics?

Overview of Unicycive Therapeutics offerings
Renazorb, a lanthanum-based phosphate binder for the management of hyperphosphatemia in patients with chronic kidney disease.
UNI-494, an investigational new drug aimed at treating acute kidney injury by preventing cell death and inflammation.
Kidney transplantation services, focusing on improving outcomes through novel therapeutic approaches.
Research in kidney disease biomarkers, aiming to enhance diagnostic methods and therapeutic monitoring.
Consulting and partnership services for the development and commercialization of kidney disease treatments and diagnostics.

Who is in the executive team of Unicycive Therapeutics?

Unicycive Therapeutics leadership team
  • Dr. Shalabh K. Gupta M.D., MPA
    Dr. Shalabh K. Gupta M.D., MPA
    Founder, Chairman, CEO & President
  • Dr. Pramod  Gupta Ph.D.
    Dr. Pramod Gupta Ph.D.
    Executive Vice President of Pharmaceutical & Business Operations
  • Mr. Douglas  Jermasek M.B.A.
    Mr. Douglas Jermasek M.B.A.
    Executive Vice President of Corporate Strategy
  • Mr. John W. Townsend CPA
    Mr. John W. Townsend CPA
    Chief Financial Officer